Azacitidine has limited activity in 'real life' patients with MDS and AML: A single centre experience

Hematological Oncology

Volumn 30, Issue 2, 2012, Pages 76-81

  Ozbalak, Murat ^a   Cetiner, Mustafa ^b   Bekoz, Huseyin ^c   Atesoglu, Elif Birtas ^d   Ar, Cem ^e   Salihoglu, Ayse ^a   Tuzuner, Nukhet ^a   Ferhanoglu, Burhan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b AMERICAN HOSPITAL   (Turkey)

^c MEMORIAL HOSPITAL   (Turkey)

^d KOCAELI UNIVERSITY   (Turkey)

^e ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Acute myeloid leukaemia; Azacitidine; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Indexed keywords

AZACITIDINE; CYTARABINE; ERYTHROPOIETIN; HYDROXYUREA; IDARUBICIN; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES;

EID: 84861814912     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.986     Document Type: Article

References (17)

1. Valent P, Horny HP, Bennett JM, et al.Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference.Leuk Res 2007;31:727-736.
2. Bennett JM, Catovsky D, Daniel MT, et al.Proposals for the classification of the myelodysplastic syndromes.Br J Haematol 1982;51:189-199.
3. Vardiman JW, Thiele J, Arber DA, et al.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.Blood 2009;114:937-951.
4. Greenberg P, Cox C, LeBeau MM, et al.International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood 1997;89:2079-2098.
5. VonHoff D, Stark M, Muggia F.5-Azacytidine, a new anticancer drug with effectiveness in acute myelogenous leukemia.Ann Intern Med 1976;85:237-245.
6. Silverman LR, Demakos EP, Peterson BL, et al.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.J Clin Oncol 2002;20:2429-2440.
7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.Lancet Oncol 2009;10:223-232.
8. Lyons RM, Cosgriff TM, Modi SS, et al.Hematologic response of three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.J Clin Oncol 2009;27:1850-1856.
9. Cheson BD, Bennett JM, Kantarjian H, et al.Report of an international working group to standardize response criteria for myelodysplastic syndromes.Blood 2000;96:3671-3674.
10. ECOG Common Toxicity Criteria. Accessed on 15 January 2011.
11. Silverman LR, McKenzie DR, Peterson BL, et al.Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B.J Clin Oncol 2006;24:3895-3903.
12. García R, LLorente DM, Bargay J, et al.Azacitidine in compassionate use: response to therapy, survival, and prognostic factors in 200 patients diagnosed with MDS or AMLBlood (ASH Annual Meeting Abstracts) 2010;116: Abstract 2933.
13. García R, LLorente DM, Bargay J, et al.Effectiveness of various dosage regimes of azacitidine in patients with myelodysplastic syndromes: safety and efficacy final data from the Spanish Azacitidine Compassionate Use RegistryBlood (ASH Annual Meeting Abstracts) 2010;116: Abstract 1853.
14. Isabella C, Avanzini P, Merli F.5-Azacitidine in patients with myelodysplasia and acute myeloid leukemia: a single center experienceBlood (ASH Annual Meeting Abstracts) 2010;116: Abstract 4969.
15. Prebet T, Sun Z, Ketterling R, et al.A 10 day schedule of azacitidine induces more complete cytogenetic remissions than the standard schedule in myelodysplasia and acute myeloid leukemia with myelodysplasia-related changes: results of the E1905 US Leukemia Intergroup StudyBlood (ASH Annual Meeting Abstracts) 2010;116: Abstract 4013.
16. Gore S, Fenaux P, Santini V, et al. Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients with higher-risk MDS. ASCO Annual Meeting2010; Abstract 6503.
17. Teichman ML, Wetzstein AG, Ho VQ, Lancet JE, List AF, Komrokji RS.Efficacy of azacitidine in the treatment of chronic myelomonocytic leukemiaBlood (ASH Annual Meeting Abstracts) 2010;116: Abstract 4017.